# Diabetes Research Hub — Monitor Report

**Generated:** 2026-05-10 (automated scheduled run)
**Scope:** Review of latest script outputs in `Analysis/Results/`, snapshot diffs since 2026-05-01, and a brief web check for breaking news
**Validation level (per Research Doctrine):** BRONZE for analytical findings; observational diffs are direct (verifiable from snapshot files)

---

## File System Status

All four primary data products are present and fresh:

| File | Last modified | Status |
|------|---------------|--------|
| `hub_monitor_report.md` | 2026-05-10 07:05 | Fresh |
| `clinical_trials_latest.json` | 2026-05-10 07:05 | Fresh (786 trials) |
| `pubmed_recent_latest.json` | 2026-05-10 07:05 | Fresh (140 unique papers, 30-day lookback) |
| `literature_gap_report.md` | 2026-05-09 08:10 | Fresh |
| `literature_gap_data.json` | 2026-04-20 15:35 | **STALE (20 days old, >14-day threshold)** |

The `hub_monitor.py` scan flagged 548 result files older than 14 days — most are dated snapshot archives (expected). The single user-facing concern is `literature_gap_data.json`, which underpins the gap analysis but has not been refreshed since the gap-report was regenerated. The May 9 report appears to have been regenerated against the same April 20 underlying data.

---

## Clinical Trial Changes

**Source:** `clinical_trials_latest.json` (generated 2026-05-10T07:05:04, ClinicalTrials.gov API v2)

### Headline category counts
- T1D Cure & Cell Therapy: 151
- T1D Immunotherapy & Prevention: 71
- T2D Novel Therapies (Phase 2–3): 139
- Diabetes Technology (Devices): 222
- Diabetes Recently Completed with Results: 275
- **Total tracked:** 786

### Same-day diff (2026-05-09 → 2026-05-10)
Per `hub_monitor_report.md`: 0 new trials, 0 removed, 0 status changes, 0 new results. Trial corpus is stable day-over-day.

### 9-day diff (since 2026-05-01)
- **12 trials added** (mix of newly registered and newly indexed completions)
- 2 trials dropped (NCT07163624 UBT251 Phase II; NCT07276776 Omnipod M evaluation — both ACTIVE_NOT_RECRUITING in old snapshot, possibly re-categorized)
- **2 status changes** worth noting:
  - NCT07135531 (CGM in underserved population) NOT_YET_RECRUITING → RECRUITING
  - NCT07415954 (Novo Nordisk NNC0662-0419 dose-finding) NOT_YET_RECRUITING → RECRUITING
- **7 new results postings** since 2026-05-01 — all academic/observational; none are pivotal Phase 3 readouts

### Phase 3 RECRUITING trials of note (43 total)
Newest five Phase 3 trials in active recruitment:

| NCT | Sponsor | Start | Title (truncated) |
|-----|---------|-------|-------------------|
| NCT07548996 | Nanjing Medical University | 2026-04-27 | Open-label dimethyl fumarate in adults with T1D |
| NCT07351058 | Hoffmann-La Roche | 2026-03-23 | Enicepatide (RO7795068) in obesity/T2D |
| NCT07394114 | Hangzhou Zhongmei Huadong | 2026-02-24 | HDM1005 in T2D not controlled by diet/exercise |
| NCT07400653 | Pfizer | 2026-02-24 | PF-08653944 in obesity/overweight |
| NCT07222332 | Eli Lilly | 2026-02-05 | Baricitinib to preserve beta-cell function (children/adults new-onset T1D) |

### Key-organization Phase 3 status (Vertex / Lilly / Novo / Sana)
- **Vertex VX-880 (zimislecel):** NCT04786262 and NCT06832410 both **RECRUITING Phase 3** — pivotal islet-cell program advancing
- **Lilly baricitinib T1D:** Two Phase 3 trials (NCT07222137 delay of stage-3 T1D in at-risk children; NCT07222332 beta-cell preservation in new-onset) both **RECRUITING** since Q1 2026
- **Lilly tirzepatide / orforglipron / retatrutide:** Multiple ACTIVE_NOT_RECRUITING Phase 3 — readouts pending (orforglipron already FDA-approved for weight loss as Foundayo per public sources)
- **Novo Nordisk CagriSema:** NCT06534411 ACTIVE_NOT_RECRUITING; new Phase 3 program NCT07564414 NOT_YET_RECRUITING (added since 2026-05-01)
- **Novo Nordisk insulin icodec (weekly insulin):** NCT07076199 RECRUITING Phase 3 in pediatric/adult populations
- **Sana Biotechnology:** No active Phase 3 in tracked corpus (ongoing early-phase work per public reporting on UP421 hypoimmune beta cells)

---

## PubMed Highlights

**Source:** `pubmed_recent_latest.json` (lookback 30 days, 16 alert domains queried, 140 unique papers).

### Domain volume (last 30 days, alert hits)
Highest activity: T2D GLP-1 New (129 raw mentions), Diabetes AI/ML (196), Diabetes Biomarker (144), Diabetes Microbiome (120). Lowest: GLP-1 Pharmacogenomics (1), LADA (3), Drug Repurposing (4), Epigenetics (8). The pharmacogenomics and LADA gaps mirror the structural gaps flagged in the gap-analysis report.

### Cross-domain papers (papers tagged in 2+ domains) — 15 total
The five highest-priority cross-domain hits for the doctrine's Tier 1 areas:

1. **PMID 42104727** — *Stem cell-based therapies for type 1 diabetes: progress in differentiation, clinical translation, and immune protection.* (Animal models and experimental medicine, May 9) — T1D Stem Cell Cure × Diabetes Gene Therapy. **New today.**
2. **PMID 42051156** — *Considerations for the clinical use of teplizumab in stage 2 T1D: BSPED Consensus Statement.* (Diabetic Medicine, Apr 29) — T1D Immunotherapy × Key Therapy: teplizumab. Direct clinical-practice guidance.
3. **PMID 42034968** — *Bone marrow-derived cells in experimental autoimmune T1D: immunomodulatory and regenerative effects.* (BMC Immunology, Apr 25) — T1D Stem Cell Cure × T1D Immunotherapy.
4. **PMID 42078397** — Loss-of-function variant in [gene name truncated] (medRxiv preprint, Apr 20) — T2D Remission × Diabetes Gene Therapy.
5. **PMID 42097137** — *Multi-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome.* (Cell, May 6) — Diabetes Biomarker × Diabetes Drug Repurpose. High-impact venue, drug-repurposing relevance.

Other cross-domain hits cluster in Diabetes AI/ML × Multi-Omics, Microbiome × Multi-Omics, and Gene Therapy × Complications (lipid-nanoparticle delivery for diabetic retinopathy NCT-style preclinical work).

### Key-therapy mentions (last 30 days)
| Therapy | Papers |
|--------|--------|
| dapagliflozin | 5 (25 mentions) |
| orforglipron | 4 |
| icodec | 3 |
| teplizumab | 3 |
| baricitinib | 2 |
| retatrutide | 2 |
| zimislecel | 0 |
| CagriSema | 0 |

Notable individual-paper hits beyond the tracked therapy list: tirzepatide vs semaglutide head-to-head meta-analysis (PMID 42100257); tirzepatide for obesity in T1D (PMID 42097660); tirzepatide/semaglutide in rheumatic disease (PMID 42101387); efsubaglutide alfa added to metformin (PMID 42103705).

### Snapshot delta since 2026-05-01 (PubMed)
104 net-new papers added in 9 days (rolling 30-day window). Day-over-day (May 9→May 10): 2 new, 5 dropped, including the cross-domain stem-cell review above.

---

## Gap Analysis Summary

**Source:** `literature_gap_report.md` (regenerated 2026-05-09 against `literature_gap_data.json` from 2026-04-20).

### Top under-researched intersections (Gap Score 100, BRONZE validation)
1. **Beta Cell Regen × Health Equity** — 0 joint pubs; no equity analysis of emerging cell therapies.
2. **Insulin Resistance × Islet Transplant** — 1 joint pub; affects graft survival but barely studied.
3. **Islet Transplant × Drug Repurposing** — 0 joint pubs; computational repurposing of immunosuppressants for islet protection unexplored.
4. **Islet Transplant × Health Equity** — 0 joint pubs; access to limited transplant centers not analyzed.
5. **Gene Therapy × LADA** — 0 joint pubs; LADA's autoimmune mechanism is a candidate for gene-therapy approaches.

(LADA appears in 6 of the top 15 gaps — a recurring structural finding that aligns with the doctrine's emphasis on LADA underdiagnosis as a Tier 1 contribution area.)

### Tier 1 alignment (per `RESEARCH_DOCTRINE.md` themes referenced in prior outputs)
The Beta Cell Regen × Health Equity, Drug Repurposing × Health Equity, and Gene Therapy × LADA intersections all map directly to the hub's stated contribution priorities (equity-of-access analyses for emerging therapies; repurposing screens for under-served subgroups). These are actionable synthesis targets where computational work — not new wet-lab data — can fill the gap.

---

## Breaking News (web check, last ~7 days)

Filtered to genuinely significant items (Phase 3 readouts, FDA actions, major publications):

- **MannKind Afrezza pediatric expansion** — PDUFA decision May 29, 2026. If approved, first needle-free inhaled-insulin option for pediatric T1D/T2D. *Worth watching for downstream tracker update at month-end.*
- **Lilly Foundayo (orforglipron) FDA approval** — Already approved for weight loss as the only oral GLP-1 without food/water timing restrictions. Cross-references the orforglipron Phase 3 trials in our tracker (NCT06972472, NCT06993792 ACTIVE_NOT_RECRUITING).
- **Generic dapagliflozin (Farxiga)** — First generics approved 2026-04-07 (HF hospitalization risk reduction + glycemic control). Lowers cost barrier; relevant to drug-repurposing/equity gaps above.
- **Sanofi Tzield (teplizumab)** — Approved for delay of stage 3 T1D in young children (press release 2026-04-22). Reinforces relevance of PMID 42051156 BSPED consensus paper above.
- **Vertex VX-880 (zimislecel) Phase 3** — Public reporting cites 83% insulin-independence rates; corresponds to RECRUITING Phase 3 trials NCT04786262 and NCT06832410 in our tracker. Regulatory submission window 2026–2027.

No items found that would warrant an immediate doctrine-level update, but the Tzield pediatric expansion and orforglipron approval are now reflected in the tracker via results-postings.

---

## Recommended Actions

In rough priority order, with the relevant scripts called out:

1. **Re-run the literature gap analysis.** `literature_gap_data.json` is 20 days old; the May 9 gap report uses stale underlying data.
   `Run: python project1_literature_gap_analysis.py`
2. **Add PMID 42097137 (Cell, multi-cohort proteogenomics)** to the tracker as a Tier 1 cross-domain reference for Biomarker × Drug Repurposing — it sits at the intersection of two doctrine priorities and appears in a high-impact venue.
3. **Review PMID 42051156 (BSPED teplizumab consensus)** and confirm whether it shifts the doctrine's clinical-recommendation language for stage 2 T1D / pediatric Tzield use; capture in `Research_Findings_Summary.md` if so.
4. **Watch the two Lilly baricitinib Phase 3 trials (NCT07222137, NCT07222332)** — both newly recruiting in 2026 and represent a meaningful new T1D-prevention angle distinct from teplizumab. Consider a dedicated tracker row.
5. **Verify the Vertex zimislecel literature signal** — `pubmed_recent_latest.json` shows 0 zimislecel hits in the last 30 days despite very public Phase 3 progress. Recommend confirming the alert query covers both "zimislecel" and "VX-880" synonyms.
6. **MannKind Afrezza PDUFA (May 29, 2026)** — schedule a follow-up monitor pass on or after May 30 to capture the decision.
7. **No re-run needed** for the daily clinical trials and PubMed snapshots — both are fresh and the day-over-day diff is empty/minimal.

---

## Sources cited (web check)
- [FDA Drug Approval Decisions Expected in May 2026 — Cardiology Advisor](https://www.thecardiologyadvisor.com/news/fda-drug-approval-decisions-expected-in-may-2026/)
- [FDA Approves First Generic Dapagliflozin Tablets — FDA](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets)
- [FDA Approves Lilly's Foundayo (orforglipron) — Eli Lilly](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)
- [Sanofi Tzield approved for stage 3 T1D delay in young children — Sanofi](https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-3278650)
- [2025 Top T1D advances — Breakthrough T1D](https://www.breakthrought1d.org/news-and-updates/2025-top-t1d-advances-full-speed-ahead/)

---

*Generated by automated monitor (scheduled task: diabetes-hub-monitor). This is a review-only run — no source files were modified.*
